Внежелудочные проявления, ассоциированные с инфекцией Helicobacter pylori

В представленной обзорной статье освещены современные взгляды на внежелудочные проявления, ассоциированные с инфицированием Helicobacter pylori. Приведены сведения о негативном влиянии инфекции H. pylori на состояние опорно-двигательного аппарата, развитие приступов мигрени, прогрессирование диффузных заболеваний печени и риск развития рака печени. Приведены данные литературы о возможном влиянии инфекции H. pylori на формирование халитоза, тимпаносклероза, нарушения репродуктивного здоровья мужчин, колоректального рака, болезни Альцгеймера и болезни Паркинсона, преэклампсии беременных, хронической идиопатической крапивницы. Рассматриваются отрицательные связи между инфицированием H. pylori и бронхиальной астмой, а также воспалительными заболеваниями кишечника.

Ferrari S.L., Karasik D., Liu J. et al. Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study. J. Bone Miner. Res. 2004; 19: 552-9.

Figura N., Gennari L., Merlotti D. et al. Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls. Dig. Dis. Sci. 2005; 50: 847-52.

Kakehasi A.M., Mendes C.M., Coelho L.G. et al. The presence of Helicobacter pylori in postmenopausal women is not a factor to the decrease of bone mineral density. Arq. Gastroenterol. 2007; 44: 266-70.

Yang Y.X., Lewis J.D., Epstein S., Metz D.C. Long-term proton pump inhibitor therapy and risk of hip fracture. J.A.M.A. 2006; 296: 2947-53.

Chung Y.H., Gwak J.S., Hong H.W. et al. Helicobacter pylori: A possible risk factor for bone health. Korean. J. Fam. Med. 2015; 36: 239-44.

Myong Ki Baeg, Myung-Gyu Choi, Sun-Hye Ko et al. Elderly women who received Helicobacter pylori-eradicating therapy have reduced risk of low skeletal muscle mass. Clin. Interv. Aging. 2015; 10: 1771-7.

Nweneka C.V., Prentice A.M. Helicobacter pylori infection and circulating ghrelin levels - a systematic review. BMC Gastroenterol. 2011; 11: 7.

Pradhan G., Samson S.L., Sun Y. Ghrelin: much more than a hunger hormone. Curr. Opin. Clin. Nutr. Metab. Care. 2013; 16(6): 619-24.

Pacifico L., Anania C., Osborn J.F. et al. Long-term effects of Helicobacter pylori eradication on circulating ghrelin and leptin concentrations and body composition in prepubertal children. Eur. J. Endocrinol. 2008; 158(3): 323-32.

Ansari B., Basiri K., Meamar R. et al. Association of Helicobacter pylori antibodies and severity of migraine attack. Iran. J. Neurol. 2015; 14(3): 125-9.

Bakhshipour A., Momeni M., Ramroodi N. Effect of Helicobacter pylori treatment on the number and severity of migraine attacks. Zahedan J. Res. Med. Sci. 2012; 14(6): 6-8.

Hosseinzadeh M., Khosravi A., Saki K., Ranjbar R. Evaluation of Helicobacter pylori infection in patients with common migraine headache. Arch. Med. Sci. 2011; 7(5): 844-9.

Gervil M., Ulrich V., Kaprio J. et al. The relative role of genetic and environmental factors in migraine without aura. Neurology. 1999; 53(5): 995-9.

Pradalier A., Devars du Mayne J.F. Migraines and digestive disorders. Gastroenterol. Clin. Biol. 2005; 29(2): 156-61.

Faraji F., Zarinfar N., Zanjani A.T., Morteza @. The effect of Helicobacter pylori eradication on migraine: a randomized, double blind, controlled trial. Pain Physician. 2012; 15(6): 495-8.

Gasbarrini A., Gabrielli M., Fiore G. et al. Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura. Cephalalgia. 2000; 20(6): 561-5.

Crabtree J.E. Role of cytokines in pathogenesis of Helicobacter pylori-induced mucosal damage. Dig. Dis. Sci. 1998; 43(9, Suppl.): 46S-55S.

Ciancarelli I., Di M.C., Tozzi-Ciancarelli M.G. et al. Helicobacter pylori infection and migraine. Cephalalgia. 2002; 22(3): 222-5.

Jamali R., Mofid A., Vahedi H. et al, The effect of Helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized openlabel clinical trial. Hepat. Mon. 2013; 13: e14679.

Polyzos S.A., Kountouras J., Papatheodorou A. et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism. 2013; 62: 121-6.

Fukuda Y., Bamba H., Okui M. et al. Helicobacter pylori infection increases mucosal permeability of the stomach and intestine. Digestion.2001; 63(Suppl. 1): 93-6.

Eshraghian A., Hashemi S.A., Hamidian Jahromi A. et al. Helicobacter pylori infection as a risk factor for insulin resistance. Dig. Dis. Sci. 2009; 54: 1966-70.

Arslan E., Atilgan H., Yavaşoğlu I. The prevalence of Helicobacter pylori in obese subjects. Eur. J. Intern. Med. 2009; 20: 695-7.

Jeon C.Y., Haan M.N., Cheng C. et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabet. Care. 2012; 35: 520-5.

Sumida Y., Kanemasa K., Imai S. et al. Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. J. Gastroenterol. 2015; 50(9): 996-1004.

Tian X.F., Fan X.G., Fu C.Y. et al. Experimental study on the pathological effect of Helicobacter pylori on liver tissues. Zhonghua Ganzangbing Zazhi. 2005; 13: 780-3.

Salehi H., Minakari M., Yaghoutkar A. et al. The effect of Helicobacter pylori eradication on liver enzymes in patients referring with unexplained hypertransaminasemia. Adv. Biomed. Res. 2014; 3: 131.

Ponzetto A., Pellicano R., Leone N. et al. Helicobacter infection and cirrhosis in hepatitis C virus carriage: is it an innocent bystander or a troublemaker? Med. Hypothes. 2000; 54: 275-7.

Feng H., Zhou X., Zhang G. Association between cirrhosis and Helicobacter pylori infection: a meta-analysis. Eur. J. Gastroenterol. Hepatol. 2014; 26: 1309-19.

Chang S.S., Hu H.Y. H. pylori eradication lower ulcers in cirrhosis. J. Dig. Dis. 2014; 15: 451-8.

Jiang H.X., Qin S.Y., Min Z.G. et al. Association of Helicobacter pylori with elevated blood ammonia levels in cirrhotic patients: a meta-analysis. Yonsei Med. J. 2013; 54: 832-8.

Esmat G., El-Bendary M., Zakarya S., Ela M.A., Zalata K. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. J. Viral. Hepat. 2012; 19: 473-9.

Sakr S.A., Badrah G.A., Sheir R.A. Histological and histochemical alterations in liver of chronic hepatitis C patients with Helicobacter pylori infection. Biomed. Pharmacother. 2013; 67: 367-74.

Nilsson H.O., Mulchandani R., Tranberg K.G. et al. T. Helicobacter species identified in liver from patients with cholangiocarcinoma and hepatocellular carcinoma. Gastroenterology. 2001; 120: 323-4.

Huang Y., Fan X.G., Wang Z.M. et al. Identification of helicobacter species in human liver samples from patients with primary hepatocellular carcinoma. J. Clin. Pathol. 2004; 57: 1273-7.

Chen R., Fan X.G., Huang Y., Li N., Chen C.H. In vitro cytotoxicity of Helicobacter pylori on hepatocarcinoma HepG2 cells. Ai Zheng. 2004; 23: 44-9.

Ki M.R., Goo M.J., Park J.K. et al. Helicobacter pylori accelerates hepatic fibrosis by sensitizing transforming growth factor-β1-induced inflammatory signaling. Lab. Invest. 2010; 90: 1507-16.

Boonyanugomol W., Chomvarin C., Sripa B. et al. Helicobacter pylori in Thai patients with cholangiocarcinoma and its association with biliary inflammation and proliferation. HPB (Oxford). 2012; 14: 177-84.

Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-45.

van den Broek A.M., Feenstra L., de Baat C. A review of the current literature on management of halitosis. Oral. Dis. 2008; 14(1): 30-9.

Katsinelos P., Tziomalos K., Chatzimavroudis G. et al. Eradication therapy in Helicobacter pylori positive patients with halitosis: longterm outcome. Med. Princ. Pract. 2007; 16(2): 119-23.